Eye on Itch: Evommune Initiaties Phase I Study of EVO756 in CSU
Evommune, Inc. is initiating its Phase 1 first-in-human study, evaluating EVO756 in chronic spontaneous urticaria (CSU). By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. The Phase 1 study is a […]